



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 17, 2019

David Parkinson, M.D.  
President and Chief Executive Officer  
ESSA Pharma Inc.  
Suite 720, 999 West Broadway  
Vancouver, British Columbia V5Z 1K5

**Re: ESSA Pharma Inc.**  
**Registration Statement on Form F-3**  
**Filed October 9, 2019**  
**File No. 333-234136**

Dear Dr. Parkinson:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Riccardo A. Leofanti, Esq.